Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TRVI
stocks logo

TRVI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.101
-7.79%
--
--
-0.127
+40.74%
--
--
-0.137
+51.86%
Estimates Revision
The market is revising No Change the revenue expectations for Trevi Therapeutics, Inc. (TRVI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 54.79%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+54.79%
In Past 3 Month
Wall Street analysts forecast TRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRVI is 20.89 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast TRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRVI is 20.89 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.770
sliders
Low
15.00
Averages
20.89
High
25.00
Current: 12.770
sliders
Low
15.00
Averages
20.89
High
25.00
Oppenheimer
Leland Gershell
Outperform
maintain
$23 -> $24
2025-11-14
Reason
Oppenheimer
Leland Gershell
Price Target
$23 -> $24
2025-11-14
maintain
Outperform
Reason
Oppenheimer analyst Leland Gershell raised the firm's price target on Trevi Therapeutics to $24 from $23 and keeps an Outperform rating on the shares. The firm notes the company provided updates across Haduvio's development in chronic cough settings, with the plan to begin the Phase 3 IPF chronic cough program - as well as advance into Phase 2b for refractory chronic cough - in the first half of 2026. Next year should also see the start of a Phase 2 in non-IPF idiopathic lung disease chronic cough, an opportunity that may be as large as IPF CC itself. Cash runway anticipated into 2028, and Oppenheimer sees meaningful upside as Haduvio's momentum toward commercial builds for a growing group of poorly served chronic cough indications.
Morgan Stanley
Judah Frommer
Overweight
maintain
$18 -> $19
2025-11-14
Reason
Morgan Stanley
Judah Frommer
Price Target
$18 -> $19
2025-11-14
maintain
Overweight
Reason
Morgan Stanley analyst Judah Frommer raised the firm's price target on Trevi Therapeutics to $19 from $18 and keeps an Overweight rating on the shares after the company provided its third quarter update, noting incremental progress on the safety side if its Haduvio program and successful presentations at recent scientific meetings.
Clear Street
Buy
maintain
$11 -> $21
2025-11-14
Reason
Clear Street
Price Target
$11 -> $21
2025-11-14
maintain
Buy
Reason
Clear Street raised the firm's price target on Trevi Therapeutics to $21 from $11 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report. Trevi has completed the requirements for an end of Phase 2 meeting with the FDA and plans to request the meeting in Q4 to finalize its Phase 3 program in idiopathic pulmonary fibrosis-related chronic cough, the analyst tells investors in a research note. Clear cites regulatory path clarity for the target increase.
Morgan Stanley
Judah Frommer
Overweight
initiated
$18
2025-08-21
Reason
Morgan Stanley
Judah Frommer
Price Target
$18
2025-08-21
initiated
Overweight
Reason
Morgan Stanley analyst Judah Frommer initiated coverage of Trevi Therapeutics with an Overweight rating and $18 price target. The company is developing Haduvio, an extended-release formulation of nalbuphine for chronic cough, where existing therapies provide limited relief, the analyst tells investors in a research note. The firm sees a multi-billion dollar opportunity for Haduvio. The drug is "de-risked and differentiated" and should address a significant treatment gap, contends Morgan Stanley.
Raymond James
Strong Buy
downgrade
$29 -> $27
2025-08-08
Reason
Raymond James
Price Target
$29 -> $27
2025-08-08
downgrade
Strong Buy
Reason
Raymond James lowered the firm's price target on Trevi Therapeutics to $27 from $29 and keeps a Strong Buy rating on the shares. The firm believes Haduvio is the most efficacious treatment in clinical development for both IPF-chronic cough and refractory chronic cough, the analyst tells investors in a research note.
Cantor Fitzgerald
NULL -> Overweight
initiated
$25
2025-07-01
Reason
Cantor Fitzgerald
Price Target
$25
2025-07-01
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Trevi Therapeutics with an Overweight rating and $25 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Trevi Therapeutics Inc (TRVI.O) is -25.91, compared to its 5-year average forward P/E of -6.44. For a more detailed relative valuation and DCF analysis to assess Trevi Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.44
Current PE
-25.91
Overvalued PE
-1.26
Undervalued PE
-11.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.85
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.45
Undervalued EV/EBITDA
-7.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TRVI News & Events

Events Timeline

(ET)
2025-12-04
07:40:00
Trevi Therapeutics Appoints David Hastings as CFO
select
2025-11-13 (ET)
2025-11-13
16:10:47
Trevi Therapeutics Announces Q3 Earnings Per Share of 8 Cents, Below Consensus Estimate of 10 Cents
select
2025-08-07 (ET)
2025-08-07
16:16:39
Trevi Therapeutics reports Q2 EPS (9c), consensus (10c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-04PRnewswire
Trevi Therapeutics Appoints New CFO to Drive Haduvio Development
  • Leadership Change: Trevi Therapeutics announced that David Hastings will assume the role of Chief Financial Officer on January 6, 2026, bringing over 25 years of financial leadership experience in the biopharmaceutical industry, which is expected to drive the development of the Haduvio project.
  • Funding Achievements: Throughout his career, Hastings has raised over $2 billion in equity and debt financing, a capability that will provide Trevi with the necessary financial support to advance its clinical trials and commercialization efforts.
  • Market Demand Opportunity: Haduvio targets chronic cough treatment, addressing the urgent needs of approximately 150,000 U.S. patients with IPF and 228,000 with non-IPF ILD, which is expected to fill a market gap and enhance the company's competitiveness.
  • Strategic Development Phase: Hastings' appointment comes as Trevi enters a critical Phase 3 development stage, and his extensive experience is anticipated to accelerate Haduvio's market introduction, enhancing long-term value for both patients and shareholders.
[object Object]
Preview
8.0
11-21Newsfilter
Harvest ETFs Reveals Distribution Plans for November 2025

  • Monthly Distributions Announcement: Harvest Portfolios Group Inc. has announced monthly distributions for various Harvest ETFs for November 2025, with payments scheduled for December 5, 2025, to unitholders of record on November 28, 2025.

  • Distribution Details: The distributions vary by ETF, with amounts ranging from $0.0250 to $0.4300 per unit, depending on the specific ETF and its currency denomination.

  • Estimated Distribution for Canadian T-Bill ETF: An estimated distribution of $0.0935 per unit for the Harvest Canadian T-Bill ETF will also be paid on December 5, 2025, with the final amount to be confirmed on November 27, 2025.

  • Company Background: Harvest Portfolios Group Inc., founded in 2009, manages over $9.6 billion in assets and focuses on long-term wealth preservation through high-quality business investments, utilizing various covered call strategies across its ETFs.

[object Object]
Preview
4.0
11-21Benzinga
Leerink Partners Keeps Outperform Rating for Trevi Therapeutics and Increases Price Target to $16

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Trevi Therapeutics Inc (TRVI) stock price today?

The current price of TRVI is 12.77 USD — it has decreased -3.04 % in the last trading day.

arrow icon

What is Trevi Therapeutics Inc (TRVI)'s business?

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

arrow icon

What is the price predicton of TRVI Stock?

Wall Street analysts forecast TRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRVI is 20.89 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Trevi Therapeutics Inc (TRVI)'s revenue for the last quarter?

Trevi Therapeutics Inc revenue for the last quarter amounts to -13.92M USD, decreased -1.21 % YoY.

arrow icon

What is Trevi Therapeutics Inc (TRVI)'s earnings per share (EPS) for the last quarter?

Trevi Therapeutics Inc. EPS for the last quarter amounts to -10892000.00 USD, increased 13.98 % YoY.

arrow icon

What changes have occurred in the market's expectations for Trevi Therapeutics Inc (TRVI)'s fundamentals?

The market is revising No Change the revenue expectations for Trevi Therapeutics, Inc. (TRVI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 54.79%.
arrow icon

How many employees does Trevi Therapeutics Inc (TRVI). have?

Trevi Therapeutics Inc (TRVI) has 26 emplpoyees as of December 13 2025.

arrow icon

What is Trevi Therapeutics Inc (TRVI) market cap?

Today TRVI has the market capitalization of 1.64B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free